7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺
![7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺结构式](https://image.chemsrc.com/caspic/482/1012054-59-9.png)
7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺结构式
|
常用名 | 7-[[4-(3-乙炔基苯基氨基)-7-甲氧基喹唑啉-6-基]氧基]-N-羟基庚酰胺 | 英文名 | CUDC-101 |
|---|---|---|---|---|
| CAS号 | 1012054-59-9 | 分子量 | 434.488 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | N/A | |
| 分子式 | C24H26N4O4 | 熔点 | 174-177ºC | |
| MSDS | 中文版 美版 | 闪点 | N/A |
|
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.
J. Med. Chem. 53 , 2000-2009, (2010) By incorporating histone deacetylase (HDAC) inhibitory functionality into the pharmacophore of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors, we synthesized a novel series of compounds with potent, ... |
|
|
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Cancer Res. 70 , 3647-3656, (2010) Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers. However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired d... |
期刊文献综述：
更多...